Evidence map›Paper›PMID 40697370›Full record

ArticleFrontiers in oncology2025

Nomogram based on tumor burden score for prediction of prognosis of patients with hepatocellular carcinoma before hepatectomy.

Qianru Xiao, Zhengqing Lei, Anfeng Si, Xuewu Tang, Facai Yang, Weihu Ma, Cheng Chi, Qiushi Yu, Yigang He, Haolan Tang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Qianru XiaoDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Zhengqing LeiDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Anfeng SiDepartment of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Xuewu TangDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Facai YangDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Weihu MaDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Cheng ChiDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Qiushi YuDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Yigang HeDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Haolan TangDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Tianhang SuDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Fangyuan HuDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Jianning LuDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Youheng YuDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Ziqi LiuDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.
Pinghua YangDepartment of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Zhangjun ChengDepartment of Hepatobiliary and Pancreatic Surgery, Zhongda Hospital, Southeast University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To develop nomogram models predicting the prognosis for patients with hepatocellular carcinoma (HCC) before hepatectomy. Methods: Patients treated at the Eastern Hepatobiliary Surgery Hospital and Zhongda Hospital, Southeast University, from January 2012 to July 2014, were retrospectively enrolled. Prediction models for overall survival (OS) and recurrence-free survival (RFS) were constructed. Results: A total of 1117 patients with HCC were enrolled in this study, and were divided into a training cohort (n=838) and a validation cohort (n=279). A prediction model for OS in the training cohort (OS-nomo, C-index=0.71), including alpha-fetoprotein (AFP), estimated hepatectomy extent, and tumor burden score (TBS) as independent factors (all P<0.05), was constructed. For clinical application, we stratified all patients into three distinct risk groups: low-, medium-, and high-risk group for OS, based on total points (TPs). Patients undergoing major hepatectomy, with AFP>20 ng/mL and high level of TBS had the worst OS. Conclusion: When selecting patients with HCC for hepatectomy, factors including sex, CPS, AFP level, estimated hepatectomy extent, and TBS should be carefully considered. OS-nomo model could serve as important tool for personalized survival prediction.

Indexed as

alphafetoprotein (AFP)estimated hepatectomy extenthepatectomyhepatocellular carcinoma (HCC)tumor burden score (TBS)

Identifiers

PMID40697370
PMCPMC12279504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.